NCT05266261

Use of Ibandronate in Diabetic Patients

Efficacy of Bisphosphonate Therapy on Postmenopausal Osteoporotic Women With and Without Diabetes: a Prospective Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 121 (actual)
• Sponsor: Yeouido St. Mary's Hospital · Academic / Other
• Sex: Female
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine whether monthly oral administration of ibandronate to postmenopausal osteoporosis patients with type 2 diabetes differs in safety and efficacy compared to patients without diabetes.

Detailed description

There are two major considerations in the use of bisphosphonates in diabetic patients. * The low rate of bone turnover in diabetic patients is at risk of side effects such as excessive inhibition of bone turnover associated with the use of bisphosphonates. * A decrease in osteocalcin following bisphosphonate use may lead to deterioration of glucose metabolism. The efficacy of ibandronate in T2DM is not thought to be significantly different based on previous studies, but there is few study on ibandronate.

Conditions

• Osteoporosis, Postmenopausal
• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Ibandronate Oral Tablet	150 mg of ibandronate + 24,000 IU of cholecalciferol

Timeline

• Start date: 2018-10-01
• Primary completion: 2021-08-30
• Completion: 2022-01-31
• First posted: 2022-03-04
• Last updated: 2022-03-04

Locations

1 site across 1 country: South Korea